Probiotics and budesonide for IgA nephropathy
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether taking a probiotic supplement along with an enteric-coated budesonide capsule (a medicine that reduces inflammation) can help people with IgA nephropathy. It may help reduce protein in the urine and protect kidney function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- A kidney biopsy must have confirmed your IgA nephropathy.
- Your urine protein level must be at least 0.75 grams per day (or a protein-to-creatinine ratio of 0.5 or higher).
- Your kidney function (eGFR) must be 30 or higher (measured by a standard test).
- You must not have taken antibiotics, steroids, other immune-suppressing drugs, or probiotic supplements in the last 3 months.
- You must not have certain serious health conditions (like severe gut problems, cancer, heart attack, stroke, or poorly controlled diabetes).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether immunosuppressive therapy (medicine that calms the immune system) helps people with IgA nephropathy and moderately to severely reduced kidney function. It is intended for adults with confirmed IgA kidney disease who still have significant protein in the urine despite standard blood-pressure kidney protection treatment.
This trial tests whether a special steroid capsule called budesonide can help treat IgA nephropathy, a kidney disease where your immune system damages the kidneys. You would take this medication along with standard care to see if it slows kidney damage and reduces protein in your urine.
This trial tests starting a special form of budesonide (Nefecon) early in people with IgA nephropathy, a kidney disease. The goal is to see if it can reduce protein in the urine and protect kidney function.
This trial looks at how bacteria in the gut (microbiome) and substances in the body (metabonomics) relate to IgA nephropathy, a kidney condition. The goal is to understand patterns that may help explain the disease and improve future care.
This trial tests whether hydroxychloroquine can help slow kidney damage in people with IgA nephropathy. You may qualify if you have this kidney disease, are already on two standard medicines (RAAS inhibitors and SGLT2 inhibitors), and have ongoing protein in your urine.
This trial tests an experimental pill (NTQ5082) for people with IgA nephropathy, a kidney disease that can cause protein in the urine and kidney damage. The goal is to see if the drug can reduce protein in the urine and protect kidney function.
Hear when a new Glomerulonephritis, IGA trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.